Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOV-4001 in Advanced Melanoma or NSCLC
NCT05361174Phase 2Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Jul 2022
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of IOV-4001 in melanoma and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoints: Safety of IOV-4001 up to 1 Year and Objective Response Rate up to 60 months. Started Jul 2022; status: recruiting.
02
Drugs
IOV-4001
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05361174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361174.